Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILUVIEN in chronic diabetic macular edema
NCT02472366Phase 4Completed
- Sponsor
- Alimera Sciences
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, open-label trial of fluocinolone acetonide intravitreal implant in diabetic macular edema (DME) (2 cohorts), sponsored by Alimera Sciences. Primary endpoint: Best Corrected Visual Acuity at 12 months. Started Jan 2014; status: completed.
02
Drugs
fluocinolone acetonide intravitreal implant
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02472366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472366.